EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects

Piotr Olejnik iD, Zuzanna Roszkowska iD, Sylwia Adamus iD, Kaja Kasarełło iD

Pharmacological Reports · 2024-10 · 76 (5) · 926-943

DOI: 10.1007/s43440-024-00642-0 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacological Reports, online erschienen am 23.08.2024. Verfasst von Piotr Olejnik und 3 weiteren Autor:innen. Beteiligte Einrichtung: Chair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Po…. Hauptthemen laut MEDLINE: Multiple Sclerosis. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 161 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple sclerosis (MS) is a chronic autoimmune disease characterized by pathological processes of demyelination, subsequent axonal loss, and neurodegeneration within the central nervous system. Despite the availability of numerous disease-modifying therapies that effectively manage this condition, there is an emerging need to identify novel therapeutic targets, particularly for progressive forms of MS. Based on contemporary insights into disease pathophysiology, ongoing efforts are directed toward developing innovative treatment modalities. Primarily, monoclonal antibodies have been extensively investigated for their efficacy in influencing specific pathological pathways not yet targeted. Emerging approaches emphasizing cellular mechanisms, such as chimeric antigen receptor T cell therapy targeting immunological cells, are attracting increasing interest. The evolving understanding of microglia and the involvement of ferroptotic mechanisms in MS pathogenesis presents further avenues for targeted therapies. Moreover, innovative treatment strategies extend beyond conventional approaches to encompass interventions that target alterations in microbiota composition and dietary modifications. These adjunctive therapies hold promise as complementary methods for the holistic management of MS. This narrative review aims to summarize current therapies and outline potential treatment methods for individuals with MS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisHumansAnimalsAntibodies, Monoclonal

Stichwörter der Autor:innen

Disease-modifying therapyMultiple sclerosisNew therapiesTreatment strategiesTreatment targets

Substanzen

Antibodies, Monoclonal

Autor:innen und Institutionen

  • Chair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Poland.
  • Biomedical Physics Division, Faculty of Physics, University of Warsaw, Warsaw, Poland.
  • Chair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Poland. kaja.kasarello@wum.edu.pl.

ORCID-Profile: Piotr Olejnik, Zuzanna Roszkowska, Sylwia Adamus, Kaja Kasarełło

Zitieren

APA

Olejnik, P., Roszkowska, Z., Adamus, S., & Kasarełło, K. (2024). Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects. Pharmacological Reports, 76(5), 926-943. https://doi.org/10.1007/s43440-024-00642-0

Vancouver

Olejnik P, Roszkowska Z, Adamus S, Kasarełło K. Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects. Pharmacological Reports. 2024;76(5):926-943. doi:10.1007/s43440-024-00642-0

BibTeX
@article{Olejnik2024,
  author = {Olejnik, Piotr and Roszkowska, Zuzanna and Adamus, Sylwia and Kasarełło, Kaja},
  title = {Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects},
  journal = {Pharmacological Reports},
  year = {2024},
  volume = {76},
  number = {5},
  pages = {926--943},
  doi = {10.1007/s43440-024-00642-0}
}
Kostenlos starten →